Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells

Proceedings of the National Academy of Sciences of the United States of America
Eric DobrzynskiRoland W Herzog

Abstract

Treatment of genetic disease such as the bleeding disorder hemophilia B [deficiency in blood coagulation factor IX (F.IX)] by gene replacement therapy is hampered by the risk of immune responses to the therapeutic gene product and to the gene transfer vector. Immune competent mice of two different strains were tolerized to human F.IX by hepatic gene transfer mediated by adenoassociated viral vector. These animals were subsequently challenged by systemic administration of an E1/E3-deleted adenoviral vector, which is known to induce a cytotoxic T lymphocyte response to the transgene product. Immune tolerance prevented cytotoxic T lymphocyte activation to F.IX and CD8(+) cellular infiltrates in the liver. Moreover, a sustained and substantial increase in hepatic F.IX expression from the adenoviral vector was achieved despite in vitro T cell responses to adenoviral antigens. Cytolytic responses to therapeutic and to viral vector-derived antigens had been prevented in vivo by activation of regulatory CD4(+) T cells, which mediated suppression of inflammatory lymphocyte responses to the liver. This result suggests that augmentation of regulatory T cell activation should provide new means to avoid destructive immune responses in gene ...Continue Reading

References

Apr 2, 1996·Proceedings of the National Academy of Sciences of the United States of America·J WalterK A High
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·P A FieldsK A High
Feb 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·Z X LiuG Dennert
Apr 5, 2002·Journal of Virology·Anne-Kathrin ZaissDaniel A Muruve
Jan 11, 2003·Science·Shohei HoriShimon Sakaguchi
Feb 8, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Gudrun SchiednerStefan Kochanek
May 3, 2003·The Journal of Clinical Investigation·Federico MingozziRoland W Herzog
May 1, 2004·Seminars in Thrombosis and Hemostasis·Roland W Herzog, Eric Dobrzynski
Jul 12, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Luis M FrancoDwight D Koeberl

❮ Previous
Next ❯

Citations

Jun 20, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Lauren E MaysJames M Wilson
Apr 14, 2006·Human Genetics·Kenneth H Warrington, Roland W Herzog
Jul 9, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Valder R ArrudaJonathan D Finn
Jan 14, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ekaterina BreousJames M Wilson
Dec 2, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Lauren E Mays, James M Wilson
Mar 18, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Suryanarayan SomanathanJames M Wilson
Mar 10, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Brad E HoffmanRoland W Herzog
Nov 30, 2007·Gene Therapy·A Zaldumbide, R C Hoeben
Feb 1, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Christopher W ThomsonLi Zhang
Mar 16, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Zhenmei Lu, Soosan Ghazizadeh
Jan 25, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hua LiHildegund Cj Ertl
Oct 4, 2013·Proceedings of the National Academy of Sciences of the United States of America·Long XuZhigang Tian
Mar 25, 2009·Human Gene Therapy·Mario CooperRoland W Herzog
Jun 14, 2013·Journal of Virology·Brittney L GurdaMavis Agbandje-McKenna
Nov 17, 2007·The Journal of Clinical Investigation·Shih-Wen LinHildegund C J Ertl
Sep 20, 2008·The Journal of Clinical Investigation·Brad E Hoffman, Roland W Herzog
Jan 6, 2015·Molecular Therapy. Methods & Clinical Development·Brandon K SackDavid M Markusic
Oct 10, 2013·EMBO Molecular Medicine·David M MarkusicRoland W Herzog
Jun 28, 2007·Human Gene Therapy·Brad E HoffmanRoland W Herzog
Jan 6, 2011·Expert Opinion on Biological Therapy·Luc J W van der LaanQiuwei Pan
Apr 14, 2006·Expert Opinion on Biological Therapy·Roland W HerzogLixin Wang
Jul 4, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Ekaterina BreousJames M Wilson
Jul 28, 2009·Journal of Thrombosis and Haemostasis : JTH·O CaoR W Herzog
Apr 27, 2007·Journal of Thrombosis and Haemostasis : JTH·G F PierceT Vandendriessche
Jun 25, 2008·Haemophilia : the Official Journal of the World Federation of Hemophilia·J AstermarkM T Reding
Jun 16, 2012·Liver International : Official Journal of the International Association for the Study of the Liver·Erawan Borkham-KamphorstRalf Weiskirchen
Sep 18, 2010·The Journal of Gene Medicine·Inge PetrusThierry VandenDriessche
Jul 17, 2013·Journal of Thrombosis and Haemostasis : JTH·M K ChuahT VandenDriessche
Aug 29, 2012·British Journal of Haematology·Donna M DiMichele
Oct 31, 2009·European Journal of Immunology·Pascal ChappertDavid-Alexandre Gross
Nov 25, 2014·Haemophilia : the Official Journal of the World Federation of Hemophilia·B K SackD M Markusic
May 14, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Scott N AshleyJames M Wilson

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.